top of page


Screen Shot 2022-12-21 at 7.24.00 AM.png

Bioengineered Probiotic Yeast Medicines (BioPYM       ) Platform


Our Vision

Fzata's vision :  Reduce health inequities by expanding patient access to therapeutic biologics.  Our oral biologics for gastrointestinal (GI) disorders will:

  1. improve patient accessibility to biologics with affordable, non-refrigerated, convenient oral capsules

  2.  improve patient compliance with no needles and no  health-care administrated infusion

  3.  improve patient outcomes given the high safety profile for chronic use

The Fzata proprietary oral Bioengineered Probiotic Yeast Medicines (BioPYM) platform empowers orally administered yeast micro-factories to make biologic therapeutics “on-site” in the gut for treatment of GI diseases.  BioPYM  can target a wide variety of GI disorders like infectious diseases, inflammation, metabolic diseases, (e.g., diabetes), colon cancer, neurodegenerative diseases, and more.  Utilizing BioPYM, we have developed a pipeline of oral biologics to treat GI-related disorders.


Fzata is proud to have been selected as "2017 Maryland Incubator Company of the Year, the Best Life Sciences Company". The award recognizes achievements by companies in  Maryland business incubators.

Contact Information

We’re happy to hear from you. Contact us today to learn more about

the live yeast biotherapeutics BioPYM platform and benefits working with us.

 Fzata, Inc. 1450 S. Rolling Rd,  Room 4.097,  Halethorpe, Maryland 21227  USA

bottom of page